Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Reprod Sci. 2009 Aug 21;16(12):1153–1164. doi: 10.1177/1933719109343310

Figure 6.

Figure 6

Relative fold difference of versican variant V3 expression in transforming growth factor β3 (TGF-β3) and α-TGF-β3 antibody treated cells: leiomyoma cells treated with TGF-β3 and α-TGF-β3 antibody versus untreated myometrial cells (A) and myometrial cells treated with TGF-β3 and α-TGF-β3 antibody versus untreated myometrial cells (B), * P< .05 and ** P< .001.